{"id":"cd3","name":"CD3","symbol":"CD3E","route":"/targets/cd3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1674","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198851","uniprot":"https://www.uniprot.org/uniprotkb/P07766/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P07766","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1975","open-targets":"https://platform.opentargets.org/target/ENSG00000198851","civic":"https://civicdb.org/genes/916/summary","oncokb":"https://www.oncokb.org/gene/CD3E","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD3E","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD3E","depmap":"https://depmap.org/portal/gene/CD3E?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000198851-CD3E","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/916","omim":"https://www.omim.org/entry/186830"}],"products":[{"id":"asp2138","name":"ASP2138","status":"phase-3","modality":"bispecific antibody","route":"/drugs/asp2138/"},{"id":"azd0486","name":"AZD0486","status":"phase-3","modality":"bispecific antibody","route":"/drugs/azd0486/"},{"id":"azd5863","name":"AZD5863","status":"phase-2","modality":"bispecific antibody","route":"/drugs/azd5863/"},{"id":"azd6621","name":"AZD6621","status":"phase-2","modality":"T-cell engager","route":"/drugs/azd6621/"},{"id":"blinatumomab","name":"Blinatumomab","status":"approved","modality":"Bispecific T-cell engager (CD19×CD3)","route":"/drugs/blinatumomab/"},{"id":"brenetafusp","name":"Brenetafusp","status":"phase-3","modality":"ImmTAC (PRAME TCR × CD3 bispecific)","route":"/drugs/brenetafusp/"},{"id":"cart84","name":"CART84","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/cart84/"},{"id":"catumaxomab","name":"Catumaxomab","status":"approved","modality":"Trifunctional bispecific antibody (EpCAM x CD3, rat-mouse hybrid)","route":"/drugs/catumaxomab/"},{"id":"elranatamab","name":"Elranatamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/elranatamab/"},{"id":"epcoritamab","name":"Epcoritamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/epcoritamab/"},{"id":"glofitamab","name":"Glofitamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3, 2:1)","route":"/drugs/glofitamab/"},{"id":"linvoseltamab","name":"Linvoseltamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/linvoseltamab/"},{"id":"m701","name":"M701","status":"phase-3","modality":"Bispecific antibody (EpCAM x CD3), intraperitoneal","route":"/drugs/m701/"},{"id":"mosunetuzumab","name":"Mosunetuzumab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/mosunetuzumab/"},{"id":"obrixtamig","name":"Obrixtamig","status":"phase-3","modality":"DLL3 x CD3 bispecific T-cell engager","route":"/drugs/obrixtamig/"},{"id":"odronextamab","name":"Odronextamab","status":"approved","modality":"Bispecific T-cell engager (CD20×CD3)","route":"/drugs/odronextamab/"},{"id":"pasritamig","name":"Pasritamig","status":"phase-3","modality":"Bispecific T-cell engager (KLK2×CD3)","route":"/drugs/pasritamig/"},{"id":"talquetamab","name":"Talquetamab","status":"approved","modality":"Bispecific T-cell engager (GPRC5D×CD3)","route":"/drugs/talquetamab/"},{"id":"tarlatamab","name":"Tarlatamab","status":"approved","modality":"Bispecific T-cell engager (DLL3×CD3)","route":"/drugs/tarlatamab/"},{"id":"tebentafusp","name":"Tebentafusp","status":"approved","modality":"ImmTAC (TCR×CD3 bispecific)","route":"/drugs/tebentafusp/"},{"id":"teclistamab","name":"Teclistamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/teclistamab/"},{"id":"tqb2825","name":"TQB2825","status":"phase-2","modality":"bispecific antibody","route":"/drugs/tqb2825/"},{"id":"ubamatamab","name":"Ubamatamab","status":"phase-2","modality":"Bispecific T-cell engager (MUC16×CD3)","route":"/drugs/ubamatamab/"},{"id":"xaluritamig","name":"Xaluritamig","status":"phase-3","modality":"Bispecific T-cell engager (STEAP1×CD3, XmAb 2+1)","route":"/drugs/xaluritamig/"}],"trials":[{"id":"dellphi-305","name":"DeLLphi-305","nct":"NCT06211036","phase":"3","status":"positive"},{"id":"epcore-dlbcl-1","name":"EPCORE DLBCL-1","nct":"NCT04628494","phase":"3","status":"mixed"},{"id":"dellphi-304","name":"DeLLphi-304","nct":"NCT05740566","phase":"3","status":"positive"},{"id":"majestec-3","name":"MajesTEC-3","nct":"NCT05083169","phase":"3","status":"positive"},{"id":"sunmo","name":"SUNMO","nct":"NCT05171647","phase":"3","status":"positive"},{"id":"aall1731","name":"COG AALL1731","nct":"NCT03914625","phase":"3","status":"positive"},{"id":"e1910","name":"ECOG-ACRIN E1910","nct":"NCT02003222","phase":"3","status":"positive"},{"id":"starglo","name":"STARGLO","nct":"NCT04408638","phase":"3","status":"mixed"},{"id":"aall1331","name":"AALL1331","nct":"NCT02101853","phase":"3","status":"mixed"},{"id":"interfant-06","name":"Interfant-06","nct":"NCT00550992","phase":"3","status":"mixed"},{"id":"tower","name":"TOWER","nct":"NCT02013167","phase":"3","status":"positive"},{"id":"nct05455320","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","nct":"NCT05455320","phase":"3","status":"active"},{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct07005128","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","nct":"NCT07005128","phase":"3","status":"active"},{"id":"nct05572515","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","nct":"NCT05572515","phase":"3","status":"active"},{"id":"nct04712097","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","nct":"NCT04712097","phase":"3","status":"active"},{"id":"nct07673887","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","nct":"NCT07673887","phase":"3","status":"recruiting"},{"id":"nct07225946","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07225946","phase":"3","status":"recruiting"},{"id":"nct06508658","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","nct":"NCT06508658","phase":"3","status":"active"},{"id":"nct06549595","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","nct":"NCT06549595","phase":"3","status":"recruiting"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"nct07213674","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","nct":"NCT07213674","phase":"3","status":"recruiting"},{"id":"nct06091865","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","nct":"NCT06091865","phase":"3","status":"recruiting"},{"id":"nct07393282","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","nct":"NCT07393282","phase":"3","status":"recruiting"},{"id":"nct06084936","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","nct":"NCT06084936","phase":"3","status":"recruiting"},{"id":"nct05623020","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","nct":"NCT05623020","phase":"3","status":"recruiting"},{"id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","nct":"NCT05020236","phase":"3","status":"recruiting"},{"id":"nct07226752","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","nct":"NCT07226752","phase":"3","status":"active"},{"id":"nct06149286","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","nct":"NCT06149286","phase":"3","status":"recruiting"},{"id":"nct06230224","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","nct":"NCT06230224","phase":"3","status":"active"},{"id":"nct05730036","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","nct":"NCT05730036","phase":"3","status":"recruiting"},{"id":"nct06097364","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","nct":"NCT06097364","phase":"3","status":"active"},{"id":"nct06091254","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","nct":"NCT06091254","phase":"3","status":"recruiting"},{"id":"nct07215585","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","nct":"NCT07215585","phase":"3","status":"recruiting"},{"id":"nct07472517","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","nct":"NCT07472517","phase":"3","status":"recruiting"},{"id":"nct07544654","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","nct":"NCT07544654","phase":"3","status":"recruiting"},{"id":"epcore-dlbcl-2","name":"EPCORE DLBCL-2","nct":"NCT05578976","phase":"3","status":"active"},{"id":"intreall-sr-2010","name":"IntReALL SR 2010","nct":"NCT01802814","phase":"3","status":"completed"},{"id":"nct06152575","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","nct":"NCT06152575","phase":"3","status":"recruiting"},{"id":"mosun-lbt-fl","name":"Mosunetuzumab against rituximab in low tumour burden follicular lymphoma","nct":"NCT06337318","phase":"3","status":"active"},{"id":"mosun-len-mzl","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","nct":"NCT06006117","phase":"3","status":"active"},{"id":"nct07778316","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","nct":"NCT07778316","phase":"3","status":"recruiting"},{"id":"prism-mel-301","name":"PRISM-MEL-301","nct":"NCT06112314","phase":"3","status":"recruiting"},{"id":"nct06117774","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","nct":"NCT06117774","phase":"3","status":"active"},{"id":"nct06191744","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT06191744","phase":"3","status":"active"},{"id":"nct05409066","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT05409066","phase":"3","status":"active"},{"id":"nct05317416","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","nct":"NCT05317416","phase":"3","status":"active"},{"id":"nct07509151","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","nct":"NCT07509151","phase":"3","status":"recruiting"},{"id":"nct07637513","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","nct":"NCT07637513","phase":"3","status":"planned"},{"id":"nct05549297","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","nct":"NCT05549297","phase":"3","status":"recruiting"},{"id":"nct06432296","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","nct":"NCT06432296","phase":"3","status":"active"},{"id":"xalute","name":"XALute","nct":"NCT06691984","phase":"3","status":"active"},{"id":"nct04980222","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","nct":"NCT04980222","phase":"2","status":"active"},{"id":"nct06502977","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","nct":"NCT06502977","phase":"2","status":"active"},{"id":"nct03888105","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","nct":"NCT03888105","phase":"2","status":"active"},{"id":"nct05060016","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","nct":"NCT05060016","phase":"2","status":"active"},{"id":"magnetismm-3","name":"MagnetisMM-3","nct":"NCT04649359","phase":"2","status":"positive"},{"id":"imcgp100-202","name":"IMCgp100-202","nct":"NCT03070392","phase":"2","status":"positive"},{"id":"d-alba","name":"D-ALBA (GIMEMA LAL2116)","nct":"NCT02744768","phase":"2","status":"positive"},{"id":"nct00377429","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","nct":"NCT00377429","phase":"2","status":"completed"},{"id":"nct06745323","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","nct":"NCT06745323","phase":"2","status":"active"},{"id":"nct06140524","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","nct":"NCT06140524","phase":"2","status":"recruiting"},{"id":"nct05955508","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","nct":"NCT05955508","phase":"2","status":"active"},{"id":"nct05207670","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","nct":"NCT05207670","phase":"2","status":"active"},{"id":"nct06550895","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","nct":"NCT06550895","phase":"2","status":"active"},{"id":"nct06577025","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","nct":"NCT06577025","phase":"2","status":"active"},{"id":"nct05283720","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","nct":"NCT05283720","phase":"2","status":"active"},{"id":"nct05451810","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","nct":"NCT05451810","phase":"2","status":"active"},{"id":"nct06500884","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","nct":"NCT06500884","phase":"2","status":"recruiting"},{"id":"nct06828991","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","nct":"NCT06828991","phase":"2","status":"recruiting"},{"id":"nct07154290","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07154290","phase":"2","status":"recruiting"},{"id":"nct07203053","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","nct":"NCT07203053","phase":"2","status":"recruiting"},{"id":"nct06854445","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","nct":"NCT06854445","phase":"2","status":"recruiting"},{"id":"nct05882058","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","nct":"NCT05882058","phase":"2","status":"recruiting"},{"id":"nct06806033","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","nct":"NCT06806033","phase":"2","status":"recruiting"},{"id":"nct06252675","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","nct":"NCT06252675","phase":"2","status":"recruiting"},{"id":"nct06534437","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","nct":"NCT06534437","phase":"2","status":"recruiting"},{"id":"nct00563836","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","nct":"NCT00563836","phase":"2","status":"completed"},{"id":"nct00189345","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","nct":"NCT00189345","phase":"2","status":"completed"},{"id":"nct07016230","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","nct":"NCT07016230","phase":"2","status":"recruiting"},{"id":"nct06526793","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","nct":"NCT06526793","phase":"2","status":"recruiting"},{"id":"nct07423585","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","nct":"NCT07423585","phase":"2","status":"recruiting"},{"id":"linker-mm1","name":"LINKER-MM1","nct":"NCT03761108","phase":"1/2","status":"positive"},{"id":"epcore-nhl-1","name":"EPCORE NHL-1","nct":"NCT03625037","phase":"1/2","status":"positive"},{"id":"majestec-1","name":"MajesTEC-1","nct":"NCT04557098","phase":"1/2","status":"positive"},{"id":"monumental-1","name":"MonumenTAL-1","nct":"NCT04634552","phase":"1/2","status":"positive"},{"id":"nct03075696","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","nct":"NCT03075696","phase":"1/2","status":"active"},{"id":"nct04246086","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","nct":"NCT04246086","phase":"1/2","status":"active"},{"id":"nct06564038","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","nct":"NCT06564038","phase":"1/2","status":"recruiting"},{"id":"nct04521231","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","nct":"NCT04521231","phase":"1/2","status":"active"},{"id":"nct07134088","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","nct":"NCT07134088","phase":"1/2","status":"active"},{"id":"nct04586426","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT04586426","phase":"1/2","status":"active"},{"id":"nct06090539","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","nct":"NCT06090539","phase":"1/2","status":"recruiting"},{"id":"nct06669247","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","nct":"NCT06669247","phase":"1/2","status":"recruiting"},{"id":"nct06988488","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","nct":"NCT06988488","phase":"1/2","status":"recruiting"},{"id":"nct05201248","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","nct":"NCT05201248","phase":"1/2","status":"active"},{"id":"nct05533775","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","nct":"NCT05533775","phase":"1/2","status":"recruiting"},{"id":"nct03671018","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","nct":"NCT03671018","phase":"1/2","status":"active"},{"id":"nct04077723","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","nct":"NCT04077723","phase":"1/2","status":"active"},{"id":"nct06634589","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","nct":"NCT06634589","phase":"1/2","status":"recruiting"},{"id":"nct07192614","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","nct":"NCT07192614","phase":"1/2","status":"recruiting"},{"id":"nct07455851","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","nct":"NCT07455851","phase":"1/2","status":"recruiting"},{"id":"nct05828511","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","nct":"NCT05828511","phase":"1/2","status":"recruiting"},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","nct":"NCT03533283","phase":"1/2","status":"active"},{"id":"nct06106945","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","nct":"NCT06106945","phase":"1/2","status":"recruiting"},{"id":"nct06829771","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","nct":"NCT06829771","phase":"1/2","status":"recruiting"},{"id":"nct07707895","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","nct":"NCT07707895","phase":"1/2","status":"planned"},{"id":"nct06814496","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","nct":"NCT06814496","phase":"1/2","status":"recruiting"},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","nct":"NCT07387926","phase":"1/2","status":"recruiting"},{"id":"nct07471789","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","nct":"NCT07471789","phase":"1/2","status":"recruiting"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"},{"id":"nct04623541","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","nct":"NCT04623541","phase":"1/2","status":"active"},{"id":"nct06005493","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","nct":"NCT06005493","phase":"1/2","status":"recruiting"},{"id":"nct04542824","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","nct":"NCT04542824","phase":"1/2","status":"active"}],"pathways":["antigen-presentation-immunoediting","extrinsic-apoptosis-death-receptors"],"companies":["abbvie","amgen","asher-bio","astellas","astrazeneca","boehringer-ingelheim","cullinan-therapeutics","cytomx-therapeutics","genmab","harpoon-therapeutics","immunocore","janux-therapeutics","johnson-johnson","lindis-biotech","pfizer","regeneron","roche-genentech","sino-biopharm","wuhan-yzy-biopharma","xencor"],"keyPapers":["paper-aall1731-blinatumomab-children-nejm-2025","paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","paper-elm-2-odronextamab-follicular-ann-oncol-2024","paper-dellphi-301-nejm-2023","paper-epcore-nhl-1-epcoritamab-jco-2023","paper-magnetismm-3-elranatamab-natmed-2023","paper-majestec-1-teclistamab-nejm-2022"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"bcma-directed","mechanism":"BCMA antigen loss (biallelic TNFRSF17 deletion, extracellular mutations)","category":"antigen"},{"class":"bcma-directed","mechanism":"T-cell exhaustion and low fitness","category":"immune-evasion"},{"class":"bcma-directed","mechanism":"Soluble BCMA decoy","category":"pharmacology"},{"class":"cd19-car-t","mechanism":"CD19-negative relapse","category":"antigen"},{"class":"cd19-car-t","mechanism":"CD19-positive relapse from poor CAR-T persistence","category":"pharmacology"},{"class":"cd19-car-t","mechanism":"Immunosuppressive microenvironment and T-cell exhaustion","category":"immune-evasion"},{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"},{"class":"anti-cd20","mechanism":"Loss or down-regulation of CD20","category":"antigen"},{"class":"anti-cd20","mechanism":"Trogocytosis (antigen shaving)","category":"antigen"},{"class":"anti-cd20","mechanism":"Effector and complement exhaustion","category":"pharmacology"},{"class":"btk-inhibitor","mechanism":"BTK C481S","category":"on-target"},{"class":"cd3-bispecific","mechanism":"Loss of the tumour-side antigen","category":"antigen"},{"class":"cd3-bispecific","mechanism":"T-cell exhaustion and depletion","category":"pharmacology"},{"class":"cd3-bispecific","mechanism":"Immunosuppressive node","category":"immune-evasion"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}